LXFR

Luxfer is a low-quality but cash-generative industrial-chemicals cyclical trading at a deceptive 61x P/E. Earnings are at a trough: FY2025 net income fell 58% to $7.7M and diluted EPS to $0.28, the third straight year of revenue erosion ($423M in FY2022 → $385M in FY2025, -1.9% YoY). Returns on capital are poor — 3.4% ROE and a 2.0% net margin — and the 61x P/E overstates value precisely because the 'E' is depressed. The offset is cash flow: operating cash flow was still $34.0M against just $7.8M of capex (~$26M free cash), which comfortably funds the $13.9M dividend even though that payout exceeds accounting earnings. On P/S (1.2x) and free-cash-flow yield the stock is closer to fairly-to-cheaply valued than the headline P/E implies, and gross profit actually rose 4.1% — so the operating business isn't collapsing, it's grinding.

The balance sheet is adequate but not comfortable. Liabilities/equity is a benign 0.63x and long-term debt fell 66% to $14.4M, but cash is thin at $8.3M and the current portion of debt jumped to $25.0M. The 10-K flags that the $125M committed banking facilities expire in October 2026 (only $15.3M drawn), so a routine-but-real refinancing sits directly ahead; a tighter renewal would pressure the dividend the equity case rests on.